|Bid||81.00 x 100|
|Ask||110.00 x 100|
|Day's range||80.75 - 83.53|
|52-week range||45.11 - 85.88|
|PE ratio (TTM)||N/A|
|Earnings date||2 May 2018 - 7 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||86.56|
Agios (AGIO) reports wider-than-expected loss in the fourth quarter of 2017. Revenues fall short of expectations. The top line also declines year over year.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.81. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...
Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investors' focus will remain on the company's pipeline on fourth-quarter earnings call.
CAMBRIDGE, Mass., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,063,433 shares at the public offering price of $67.00 per share. ...
Last year's FDA approval of Agios' (AGIO) only marketed drug Idhifa and its rapid progress on a robust pipeline during the period drive the share price consistently.
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten public offering of 7,089,553 shares of common stock at a price to the public of $67.00 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately $475 million. All of the shares in the offering are to be sold by Agios. Agios has also granted the underwriters a 30-day option to purchase from it up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions.
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to $400 million of its common stock in an underwritten public offering. Agios also intends to grant the underwriters a 30-day option to purchase from it up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering are to be sold by Agios.
A Relative Strength Rating upgrade for Agios Pharmaceuticals shows improving technical performance.
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Agios Pharmaceuticals Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors .
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today summarized key 2018 priorities in conjunction with its presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will outline how Agios’ clinical and research programs have the potential to provide meaningful benefit to a large number of patients.
NEW YORK, Jan. 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), Virtu Financial, Inc. (NASDAQ:VIRT), Tableau Software, Inc. (NYSE:DATA), Graco Inc. (NYSE:GGG), Kadmon Holdings, Inc. (NYSE:KDMN), and Titan International, Inc. (NYSE:TWI), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.
CAMBRIDGE, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the company is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 8, 2018 at 9:30 a.m. PT (12:30 p.m. ET).
Agios (AGIO) submits new drug application to the FDA for ivosidenib for relapsed or refractory acute myeloid leukemia and IDH1 mutation. The company has also filed request for a priority review.
A couple of acquisition agreements as well as pipeline news from Celgene (CELG) and Biogen were the key highlights this week in the biotech sector.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ivosidenib (AG-120), an investigational oral treatment for patients with relapsed or refractory acute myeloid leukemia (R/R AML) and an isocitrate dehydrogenase-1 (IDH1) mutation. Agios has requested priority review for the application, which, if granted, could result in a six-month review process.
A Relative Strength Rating upgrade for Agios Pharmaceuticals shows improving technical performance. Will it continue?
Companies large and small are competing to attack rare genetic mutations that cause cancer. The reason? Great science and high drug prices. The result? Soaring stock prices.
Agios (AGIO) presents new data from the dose expansion part of a phase I study, evaluating ivosidenib as a single agent for treating IDH1m glioma, at the Society for Neuro-Oncology in San Francisco.